DK3484476T3 - Meclozin-derivater til anvendelse ved forebyggelse og/eller behandling af lidelser associeret med den forårsagede inflammation - Google Patents

Meclozin-derivater til anvendelse ved forebyggelse og/eller behandling af lidelser associeret med den forårsagede inflammation Download PDF

Info

Publication number
DK3484476T3
DK3484476T3 DK17745143.2T DK17745143T DK3484476T3 DK 3484476 T3 DK3484476 T3 DK 3484476T3 DK 17745143 T DK17745143 T DK 17745143T DK 3484476 T3 DK3484476 T3 DK 3484476T3
Authority
DK
Denmark
Prior art keywords
meclozine
prevention
derivatives
treatment
disorders associated
Prior art date
Application number
DK17745143.2T
Other languages
English (en)
Inventor
Vincent Calvez
Anne-Geneviève Marcelin
Nicolas Dupin
Philippe Grange
Original Assignee
Univ Paris
Hopitaux Paris Assist Publique
Inst Nat Sante Rech Med
Centre Nat Rech Scient
Univ Sorbonne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Paris, Hopitaux Paris Assist Publique, Inst Nat Sante Rech Med, Centre Nat Rech Scient, Univ Sorbonne filed Critical Univ Paris
Application granted granted Critical
Publication of DK3484476T3 publication Critical patent/DK3484476T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D253/00Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/061,2,4-Triazines
    • C07D253/0651,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/071,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075Two hetero atoms, in positions 3 and 5
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203Retinoic acids ; Salts thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK17745143.2T 2016-07-13 2017-07-13 Meclozin-derivater til anvendelse ved forebyggelse og/eller behandling af lidelser associeret med den forårsagede inflammation DK3484476T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16305912 2016-07-13
PCT/EP2017/067774 WO2018011375A1 (en) 2016-07-13 2017-07-13 Meclozine derivatives and diclazuril derivatives for use in the prevention and/or the treatment of disorders associated to the inflammation induced by p. acnes

Publications (1)

Publication Number Publication Date
DK3484476T3 true DK3484476T3 (da) 2021-09-27

Family

ID=56511498

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17745143.2T DK3484476T3 (da) 2016-07-13 2017-07-13 Meclozin-derivater til anvendelse ved forebyggelse og/eller behandling af lidelser associeret med den forårsagede inflammation

Country Status (13)

Country Link
US (2) US11116763B2 (da)
EP (2) EP3484476B1 (da)
JP (1) JP7274076B2 (da)
KR (1) KR20190038828A (da)
CN (1) CN109963563A (da)
AU (1) AU2017297812A1 (da)
BR (1) BR112019000585A2 (da)
CA (1) CA3030624A1 (da)
DK (1) DK3484476T3 (da)
ES (1) ES2897988T3 (da)
PH (1) PH12019500076A1 (da)
SG (1) SG11201900215YA (da)
WO (1) WO2018011375A1 (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115414360A (zh) * 2022-08-30 2022-12-02 上海交通大学医学院附属仁济医院 全反式维甲酸联合抗生素在治疗假体周围感染中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1000040B1 (en) * 1997-07-10 2007-06-13 Janssen Pharmaceutica N.V. Il-5 inhibiting 6-azauracil derivatives
BR9914385A (pt) * 1998-10-08 2001-07-17 New Ace Res Company Composição útil para o tratamento e prevenção de infecções protozoárias no homem e em animais, e, método de tratamento de uma infecção protozoária no homem e em animais
US8211916B2 (en) 2000-06-20 2012-07-03 Wayne State University N- and O-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating CNS disorders therewith
KR20050091062A (ko) * 2003-01-16 2005-09-14 얀센 파마슈티카 엔.브이. 디클라주릴을 포함하는 항원충제 조성물
WO2005009342A2 (en) 2003-07-16 2005-02-03 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
BRPI0811102A2 (pt) * 2007-05-15 2014-09-23 Puretech Ventures Métodos e composições para tratar condições de pele
US8784852B2 (en) 2009-02-27 2014-07-22 Audrey Kunin Topical skin care composition
CA2762216C (en) 2009-05-18 2017-07-11 3M Innovative Properties Company Dry powder inhalers
MX2014002163A (es) 2011-08-26 2014-09-25 Wockhardt Ltd Métodos para el tratamiento de desórdenes cardiovasculares.
ES2606148T3 (es) * 2011-11-01 2017-03-22 Inopharm Limited Composición de disgregación oral de agentes antihistamínicos
WO2017034984A1 (en) * 2015-08-21 2017-03-02 The Johns Hopkins University Identification of additional anti-persister activity against borrelia burgdorferi from an fda drug library
JP2017128541A (ja) 2016-01-21 2017-07-27 学校法人東京女子医科大学 アポトーシス誘導剤

Also Published As

Publication number Publication date
EP3484476B1 (en) 2021-08-25
KR20190038828A (ko) 2019-04-09
EP3484476A1 (en) 2019-05-22
PH12019500076A1 (en) 2019-07-24
ES2897988T3 (es) 2022-03-03
JP2019521152A (ja) 2019-07-25
EP3943088A1 (en) 2022-01-26
CN109963563A (zh) 2019-07-02
CA3030624A1 (en) 2018-01-18
BR112019000585A2 (pt) 2019-07-02
US11116763B2 (en) 2021-09-14
JP7274076B2 (ja) 2023-05-16
WO2018011375A1 (en) 2018-01-18
US20200383973A1 (en) 2020-12-10
AU2017297812A1 (en) 2019-02-07
US11617748B2 (en) 2023-04-04
SG11201900215YA (en) 2019-02-27
US20190224191A1 (en) 2019-07-25

Similar Documents

Publication Publication Date Title
DK3149019T3 (da) Cholan-derivater til anvendelse ved behandling og/eller forebyggelse af FXR- og TGR5/GPBAR1-formidlede sygdomme
DK3673080T3 (da) Antisense-oligomerer til behandling af lidelser og sygdomme
DK3464266T3 (da) Substituerede indazoler, der er anvendelige til behandling og forebyggelse af allergiske og/eller inflammatoriske sygdomme hos dyr
DK3325509T3 (da) Anti-tfr antistoffer og deres anvendelse i behandling af proliferative og inflammatoriske lidelser
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
DK3395359T3 (da) Plasminogen til anvendelse til forebyggelse eller behandling af akut trombose og kronisk trombose
DK3432899T3 (da) Anvendelse af probiotika ved behandling og/eller forebyggelse af psoriasis
DK3395353T3 (da) Plasminogen til anvendelse til behandling eller forebyggelse af diabetes-mellitus-nerveskade
DK3362449T3 (da) Sibirilin-derivater til anvendelse til at forebygge og/eller behandle lidelser associeret med cellulær nekroptose
DK3303339T3 (da) Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme
DK3882250T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser
DK3189074T3 (da) Sammensætninger og metoder til behandling og forebyggelse af inflammation
DK3261642T3 (da) Quinolinderivater til anvendelse ved behandling eller forebyggelse af virusinfektioner
DK3273995T3 (da) Kombineret anvendelse af alginatoligomerer og cftr-modulatoren lumacaftor i behandlingen af tilstande associeret med cftr-dysfunktion
DK3442513T3 (da) Anvendelse af cannabidiolsyre i behandling af autismespektrumforstyrrelse og forbundne forstyrrelser
DK3484585T3 (da) Anvendelse af probiotika ved behandling og/eller forebyggelse af atopisk dermatitis
DK3160234T3 (da) Sammensætning til anvendelse til forebyggelse og behandling af oftalmisk-, hånd- eller fodbiofilmvækst
DK3532064T3 (da) Kombinationsbehandlinger omfattende imidazopyrazinoner til behandlingen af psykiatriske og/eller kognitive lidelser
DK3328864T3 (da) Terapeutiske forbindelser og sammensætninger til behandling af sociale forstyrrelser og stofmisbrugsforstyrrelser
DK3153511T3 (da) 2-acylaminothiazolderivat til anvendelse i forebyggelsen eller behandlingen af blære- og urinvejssygdomme
DK3522873T3 (da) Sammensætninger og fremgangsmåder til behandlingen af xerostomi
DK3157532T3 (da) Fremgangsmåder til behandling og forebyggelse af sygdomme med vaskulær instabilitet
DK3373922T3 (da) Sammensætninger og fremgangsmåder til anvendelse i behandlingen af homocystinuri
DK3197556T3 (da) Sammensætning til forebyggelse og/eller behandling af allergisymptomer
DK3247352T3 (da) Cebranopadol til behandling af smerter hos individer med forringet lever- og/eller forringet nyrefunktion